MedTrace Logo

A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon

NCT01531166 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2016-08-17

No results posted yet for this study

Summary

The current proposed study aims to bring answers following issues: the antiviral efficacy and safety profiles in Korean Chronic Hepatitis B (CHB) patients who are mostly infected with solely genotype C HBV, a proper duration of Pegasys® therapy post-treatment durability or accumulation of HBeAg seroconversion/HBsAg loss, preventable effect on long-term disease progression to liver cirrhosis and liver cancer. In addition, this study aims to collect more data on the efficacy and safety in a real-life clinical setting of Pegasys® therapy in patients with CHB.

Conditions

Interventions

DRUG

pegylated Interferon-alpha 2a

Pegasys 180mcg/PFS/ subcutaneous injection / Once a week

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Sang Hoon Ahn, MD. PhD · Department of Internal Medicine, Yonsei Universtiy College of Medicine,

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-08-31
Completion
2014-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01531166 on ClinicalTrials.gov